Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors"

Affiliations

• ¹ Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France.
• ² European Institute of Oncology, Milan, Italy.
• ³ Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
• ⁴ Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle.
• ⁵ Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder, USA; Clovis Oncology, Inc., Milan, Italy.
• ⁶ Institut de Recherche International Servier, Suresnes, France.
• ⁷ Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy.